Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

A review of hematopoietic cell transplantation in China: data and trends during 2008–2016

Bone Marrow Transplantation volume 52, pages 1512–1518 (2017)Cite this article

Subjects

Abstract

Hematopoietic cell transplantation (HCT) activity in China was surveyed to assess its current status. A record number of HCTs (21 884: 16 631 allogeneic (76%) and 5253 autologous (24%)) were reported by 76 centers in China between 1 January 2008 and 30 June 2016. HCT trends included continued growth in transplant activity, a continued rapid increase in haploidentical donors (HID), and slower growth for unrelated donors, matched-related donors (MRD) and cord blood transplantation (CBT). The proportion of HID HCT among allogeneic HCTs increased from 29.6% (313/1062) in 2008 to 48.8% (1939/3975) in 2015, even 51.7% (1157/2237) in the first half of 2016. During this time frame, the proportion of MRD HCTs among allogeneic HCTs decreased from 48.1% (511/1062) to 33.0% (332/3975). The proportion of unrelated donor HCTs among allogeneic HCTs decreased from 20.4 (216/1062) to 13.6% (540/3975). The proportion of CBTs among allogeneic HCTs was increased from 2.1% (22/1062) to 4.2% (184/3975). HCTs have been increasing continuously for all indications except chronic myelogenous leukemia. Severe aplastic anemia is a common HCT indication among non-malignant diseases in China. The number of cases of allogeneic HCT for this disorder has increased annually, from 59 (5.6%) in 2008 to 569 (14.3%) in 2015, even 334 (14.9%) in the first half year in 2016. This survey clearly shows recent trends for HCTs in China.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016; 51: 778–785.

    Article  CAS  Google Scholar 

  2. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant 2016; 51: 786–792.

    Article  CAS  Google Scholar 

  3. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.

    Article  CAS  Google Scholar 

  4. Yoshimi A, Suzuki R, Atsuta Y, Iida M, Lu DP, Tong W et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant 2010; 45: 1682–1691.

    Article  CAS  Google Scholar 

  5. Du H, Chen J, Qin M, Fang J, Li Z, Zhu Y et al. Pediatric hematopoietic stem cell transplantation in China: data and trends during 1998–2012. Pediatr Transplant 2015; 19: 563–570.

    Article  Google Scholar 

  6. Stem cell application group of Hematology branch of Chinese Association. Consensus on allogeneic hematopoietic stem cell transplantation in China: indication and condition regimen and donors. Chinese J Hematol 2014; 35: 775–778.

  7. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Acute Myeloid Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  8. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Acute Lymphoblastic Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  9. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Chronic Myeloid Leukemia. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  10. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site: Myelodysplastic Syndromes. NCCN: Fort Washington, PA, USA, 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  11. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978–985.

    Article  Google Scholar 

  12. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation to chemotherapy alone as post-remission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119: 5584–5590.

    Article  CAS  Google Scholar 

  13. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H et al. MRD-directed risk stratification treatment may improve outcomes of t (8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013; 121: 4056–4062.

    Article  CAS  Google Scholar 

  14. Qin YZ, Xu LP, Chen H, Jiang Q, Wang Y, Jiang H et al. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leuk Lymphoma 2015; 56: 3116–3123.

    Article  CAS  Google Scholar 

  15. Wang Y, Huang XJ . Haploidentical transplantation for the treatment of intermediate- or high-risk acute myeloid leukemia in first complete remission: guideline and practice. Chinese J Hematol 2016; 37: 721–724.

    CAS  Google Scholar 

  16. Yan CH, Jiang Q, Wang J, Xu LP, Liu DH, Jiang H et al. Superior survival of unmanipulated haploidentical HSCT compared with chemotherapy alone used as post-remission therapy in adult standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant 2014; 20: 1314–1321.

    Article  Google Scholar 

  17. Sun YQ, Wang J, Jiang Q, Xu LP, Liu DH, Zhang XH et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL. Bone Marrow Transplant 2015; 50: 20–25.

    Article  Google Scholar 

  18. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a Biologically Phase III Randomized Study. Clin Cancer Res 2016; 22: 3467–3476.

    Article  CAS  Google Scholar 

  19. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH et al. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 716–721.

    Article  Google Scholar 

  20. Xu ZL, Huang XJ, Liu KY, Chen H, Zhang XH, Han W et al. Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia. Pediatr Transplant 2016; 20: 572–580.

    Article  Google Scholar 

  21. Chen H, Liu KY, Xu LP, Chen YH, Han W, Zhang XH et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2015; 21: 1110–1116.

    Article  Google Scholar 

  22. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032–3040.

    Article  CAS  Google Scholar 

  23. Xu L, Zhu H, Hu J, Wu D, Jiang H, Jiang Q et al. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. Front Med 2015; 9: 304–311.

    Article  Google Scholar 

  24. Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49: 1146–1154.

    Article  CAS  Google Scholar 

  25. Xu LP, Xu ZL, Zhang XH, Chen H, Chen YH, Han W et al. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Biol Blood Marrow Transplant 2016; 22: 1080–1086.

    Article  CAS  Google Scholar 

  26. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  27. Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M et al. Haplo-identical transplantation for acquired severe aplastic anemia in a multi-center prospective study. Br J Haematol 2016; 175: 265–274.

    Article  Google Scholar 

  28. Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 2017; 10: 25.

    Article  Google Scholar 

  29. Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al. Who is the best donor for a related HLA-haplotype-mismatched transplant? Blood 2014; 124: 843–850.

    Article  CAS  Google Scholar 

  30. Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 2015; 8: 84–92.

    Article  Google Scholar 

  31. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al. Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125: 3956–3962.

    Article  CAS  Google Scholar 

  32. Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia 2016; 30: 2055–2063.

    Article  CAS  Google Scholar 

  33. Liu DH, Xu LP, Liu KY, Wang Y, Chen H, Han W et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transplant 2013; 48: 1519–1524.

    Article  Google Scholar 

  34. Ma YR, Huang XJ, Xu ZL, Liu KY, Chen H, Zhang XH et al. Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clin Transplant 2016; 30: 994–1001.

    Article  Google Scholar 

  35. Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Acute Leukemia Working Party of the EBMT. Haematologica 2016; 101: e352–e354.

    Article  Google Scholar 

  36. Huang XJ, Xu LP, Liu KY, Liu DH, Wang Y, Chen H et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777–4783.

    Article  CAS  Google Scholar 

  37. Mo XD, Tang BL, Zhang XH, Zheng CC, Xu LP, Zhu XY et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. Int J Cancer 2016; 139: 2106–2115.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We sincerely thank all participating centers and their staff. All participating teams are listed in the Appendix. This work was supported by the Key Program of the National Natural Science Foundation of China (Grant No. 81230013), the National Natural Science Foundation of China (Grant No. 81400145), Project TG-2015-003 supported by the Health Science Promotion Project of Beijing and the Beijing Talent fund (No. 2015000021223ZK39).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China

    L-P Xu, K-Y Liu & X-J Huang

  2. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

    L-P Xu, K-Y Liu & X-J Huang

  3. The First Affiliated Hospital of Soochow University, Soochou, China

    D-P Wu

  4. Blood Diseases Hospital, Chinese Academy of Medica, Tianjin, China

    M-Z Han

  5. The First Affiliated Hospital, Zhejiang University, Hangzhou, China

    H Huang

  6. Nanfang Hospital, Guangzhou, China

    Q-F Liu

  7. Chinese PLA General Hospital, Beijing, China

    D-H Liu

  8. Anhui Provincial Hospital, Hefei, China

    Z-M Sun

  9. Wuhan Union Hospital, Wuhan, China

    L-H Xia

  10. Shanghai Children's Medical Center, Shanghai, China

    J Chen

  11. The General Hospital of The Air Force, People's Liberation Army of China, Beijing, China

    H-X Wang

  12. Shanghai General Hospital, Shanghai, China

    C Wang

  13. Department of Pediatrics, Nanfang Hospital, Guangzhou, China

    C-F Li

  14. The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    Y-R Lai

  15. Changhai Hospital, Shanghai, China

    J-M Wang

  16. Peking Union Medical College Hospital, Beijing, China

    D-B Zhou

  17. The 307th Hospital of Chinese People's Liberation Army, Beijing, China

    H Chen

  18. Henan Cancer Center, Zhengzhou, China

    Y-P Song

  19. West China Hospital, Sichuan University, Chengdu, China

    T Liu

  20. Peking-Tsinghua Center for Life Sciences, Beijing, China

    X-J Huang

Authors
  1. L-P Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D-P Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M-Z Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Q-F Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D-H Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z-M Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L-H Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H-X Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C-F Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y-R Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J-M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D-B Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Y-P Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. T Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. K-Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. X-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Chinese Blood and Marrow Transplantation Register Group

Corresponding author

Correspondence to X-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, LP., Wu, DP., Han, MZ. et al. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant 52, 1512–1518 (2017). https://doi.org/10.1038/bmt.2017.59

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.59

This article is cited by

Search

Advanced search

Quick links